The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)-thien-3-yl-4[2-piperidin-1-ethoxyphenol]methanone hydrochloride.

Patent
   RE38968
Priority
Jul 28 1992
Filed
Feb 27 2003
Issued
Feb 07 2006
Expiry
Jul 28 2012

TERM.DISCL.
Assg.orig
Entity
Large
9
49
all paid
0. 4. A method of inhibiting post-menopausal bone loss in a post-menopausal woman in need of treatment to prevent post-menopausal osteoporosis comprising administering to said woman in need of said treatment an effective amount of 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl)ethoxyphenyl]methanone hydrochloride.
1. A method of inhibiting post-menopausal bone loss in a post-menopausal woman in need of treatment to prevent or treat post-menopausal osteoporosis comprising administering to a human said woman in need thereof of said treatment an effective amount of 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B]thien-3-yl-4-[2-(piperidin-1-yl)ethoxyphenyl]methanone hydrochloride.
0. 2. The method of claim 1 wherein said human is female.
3. The method of claim 2 1 wherein said human woman has post-menopausal osteoporosis.

This application is a division, of application Ser. No. 08/180,522 filed Jan. 12, 1994, now U.S. Pat. No. 5,393,763, which is a continuation of application Ser. No. 07/920,933 filed Jul. 28, 1992, now abandoned.

This invention relates to the discovery that a group of 2-phenyl-3-aroylbenzothiophenes is useful in the prevention of bone loss.

The mechanism of bone loss is not well understood, but in practical effect, the disorder arises from an imbalance in the formation of new healthy bone and resorption of old bone, skewed toward a net loss of bone tissue. This bone loss includes a decrease in both mineral content and protein matrix components of the bone, and leads to an increased fracture rate of, predominantly, femoral bones and bones in the forearm and vertebrae. These fractures, in turn, lead to an increase in general morbidity, a marked loss of stature and mobility, and, in many cases, an increase in mortality resulting from complications.

Bone loss occurs in a wide range of subjects, including post-menopausal women, patients who have undergone hysterectomy, patients who are undergoing or have undergone long-term administration of corticosteroids, patients suffering from Cushing's syndrome, and patients having gonadal anytime any time within the previous five years; patients with any undiagnosed or abnormal genital bleeding; patients with active, or a history of, thromboembolic disorders; patients who have impaired liver or kidney function; patients who have abnormal thyroid function; patients who are poor medical or psychiatric risks; or patients who consume an excess of alcohol or abuse drugs.

Patients in the estrogen treatment group receive 0.625 mg/day and the two raloxifene groups receive dosages of 200 and 600 mg/day, all groups receiving oral capsule formulations. Calcium carbonate, 648 mg tablets, is used as calcium supplement with all patients taking 2 tablets each morning during the course of the study.

The study is a double-blind design. The investigators and the patients do not know the treatment group to which the patient is assigned.

A baseline examination of each patient includes quantitative measurement of urinary calcium, creatinine, hydroxyproline, and pyridinoline crosslinks. Blood samples are measured for serum levels of osteocalcin, bone-specific alkaline phosphatase, raloxifene, and raloxifene metabolites. Baseline measurements also include examination of the uterus including uterine biopsy.

During subsequent visits to the investigating physician, measurements of the above parameters in response to treatment are repeated. The biochemical markers listed above that are associated with bone resorption have all been shown to be inhibited by the administration of estrogen as compared to an untreated individua. Raloxifene is also expected to inhibit the markers in estrogen deficient individuals as an indication that raloxifene is effective in inhibiting bone loss from the time that treatment is begun.

Subsequent longer term studies can incorporate the direct measurement of bone density by the use of a photon absorptiometry and the measurement of fracture rates associated with therapy.

Cullinan, George J., Black, Larry J.

Patent Priority Assignee Title
10251797, Dec 29 1999 Hill-Rom Services, Inc. Hospital bed
7454805, Dec 29 1999 Hill-Rom Services, Inc. Hospital bed
7926131, Dec 29 1999 Hill-Rom Services, Inc. Hospital bed
8030330, Mar 26 1996 Eli Lilly and Company Benzothiophenes, formulations containing same, and methods
8151387, Dec 29 1999 Hill-Rom Services, Inc. Hospital bed frame
8367105, Nov 10 2004 Teva Pharmaceutical Industries, Ltd Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
8367106, Nov 10 2004 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
8597666, Nov 10 2004 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
9009893, Dec 29 1999 Hill-Rom Services, Inc. Hospital bed
Patent Priority Assignee Title
4133814, Oct 28 1975 Eli Lilly and Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
4185108, May 10 1977 COLGATE-PALMOLIVE COMPANY, A CORP OF DE Antiosteoporotic agents
4380635, Apr 03 1981 Eli Lilly and Company Synthesis of acylated benzothiophenes
4418068, Apr 03 1981 Eli Lilly and Company Antiestrogenic and antiandrugenic benzothiophenes
4729999, Oct 12 1984 BCM TECHNOLOGIES, INC , 1610 WOODSTEAD COURT, SUITE 430, THE WOODLANDS, TX 77380 A CORP OF TX Antiestrogen therapy for symptoms of estrogen deficiency
4894373, Oct 12 1984 BCM TECHNOLOGIES, INC Antiestrogens and their use in treatment of menopause and osteoporosis
4970237, Mar 20 1987 Yale University Use of clomiphene to increase bone mass in premenopausal women
5011853, Aug 25 1989 Washington University; WASHINGTON UNIVERSITY, A CORP OF MO Compounds for treatment of cholinergic neurotoxins
5075321, Mar 24 1987 PENNSYLVANIA, THE UNIVERSITY OF Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
5118667, May 03 1991 CELTRIX PHARMACEUTICALS, INC Bone growth factors and inhibitors of bone resorption for promoting bone formation
5208031, Jun 06 1989 KELLY, PATRICK D Sexual lubricants containing zinc as an anti-viral agent
5393763, Jul 28 1992 Eli Lilly and Company Methods for inhibiting bone loss
5395842, Oct 31 1988 Endorecherche Inc. Anti-estrogenic compounds and compositions
5441947, Aug 25 1993 NEXSTAR PHARMACEUTICALS, INC Methods of inhibiting vascular restenosis
5445941, Jun 21 1993 Eli Lilly and Company Method for screening anti-osteoporosis agents
5457116, Oct 15 1993 Eli Lilly and Company Methods of inhibiting uterine fibrosis
5461065, Oct 15 1993 Eli Lilly and Company Methods for inhibiting endometriosis
5462949, Dec 21 1993 Eli Lilly and Company Methods of inhibiting fertility in women
5464845, Dec 22 1992 Eli Lilly and Company Methods for lowering serum cholesterol
5468773, Aug 25 1993 Eli Lilly and Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
5472962, Nov 15 1991 Teikoku Hormone Mfg. Co., Ltd. Benzothiophene derivative
5478847, Mar 02 1994 Eli Lilly and Company Methods of use for inhibiting bone loss and lowering serum cholesterol
5482949, Mar 19 1993 Eli Lilly and Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
5510370, Jul 22 1993 Eli Lilly and Company Parathyroid hormone and raloxifene for increasing bone mass
5534527, Jul 28 1992 Eli Lilly and Company Methods for inhibiting bone loss by treating with aroylbenzothiophenes and estrogen
5567713, Jun 24 1993 Eli Lilly and Company Hypoglycemic agents
5591753, Jan 28 1994 Eli Lilly and Company Combination treatment for osteoporosis
5624940, Dec 14 1993 Eli Lilly and Company Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof
5629425, Sep 19 1994 Eli Lilly and Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thi ophene
5641790, Mar 02 1994 Eli Lilly and Company Methods of use for inhibiting bone loss and lowering serum cholesterol
5646137, Jan 28 1994 Eli Lilly and Company Combination treatment for osteoporosis
5731327, Apr 26 1995 Eli Lilly and Company Synthesis of 3-[4-(2-aminoethoxy)benzoyl]-2-aryl-6-hydroxybenzo [b]thiophenes
5747510, Mar 02 1994 Eli Lilly and Company Pharmaceutical unit dosage formulations
5811120, Mar 02 1994 Eli Lilly and Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
5972383, Mar 02 1994 Eli Lilly and Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
6087378, Oct 13 1998 Eli Lilly and Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
6096781, Nov 14 1997 Eli Lilly and Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
6156786, Nov 14 1997 Eli Lilly and Company 2-aryl-3-aroylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome
6395769, Nov 14 1997 Eli Lilly and Company 2-arylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome
6458811, Mar 26 1996 Eli Lilly and Company Benzothiophenes formulations containing same and methods
6713494, Aug 28 1996 Eli Lilly and Company Amorphous benzothiophenes, methods of preparation and methods of use
EP62505,
EP68563,
EP605193,
EP68563,
GB2097788,
NO304924,
WO9310113,
WO9310741,
/
Executed onAssignorAssigneeConveyanceFrameReelDoc
Feb 27 2003Eli Lilly and Company(assignment on the face of the patent)
Date Maintenance Fee Events
Mar 20 2007M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Feb 07 20094 years fee payment window open
Aug 07 20096 months grace period start (w surcharge)
Feb 07 2010patent expiry (for year 4)
Feb 07 20122 years to revive unintentionally abandoned end. (for year 4)
Feb 07 20138 years fee payment window open
Aug 07 20136 months grace period start (w surcharge)
Feb 07 2014patent expiry (for year 8)
Feb 07 20162 years to revive unintentionally abandoned end. (for year 8)
Feb 07 201712 years fee payment window open
Aug 07 20176 months grace period start (w surcharge)
Feb 07 2018patent expiry (for year 12)
Feb 07 20202 years to revive unintentionally abandoned end. (for year 12)